Melane Sampson, Author at BioTuesdays

Developments

Myricx to be acquired by Novartis for $1.5B

Closely held Myricx Bio has announced that it has reached an agreement to be acquired by Novartis (NYSE: NVS) for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. The acquisition...

July 14, 2026

Developments

USPTO grants Immutep new patent for eftilagimod alfa combined with PD-1 pathway inhibitors

Immutep (ASX: IMM; NASDAQ: IMMP) has announced that the United States Patent and Trademark Office (USPTO) granted a new patent for eftilagimod alfa in combination with a PD-1 pathway inhibitor for the treatment of...

July 14, 2026

Developments

Envoy reports improvement in speech perception in trial of cochlear implant

Envoy Medical (NASDAQ: COCH) has announced positive 12-month data from the first ten participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim cochlear implant...

July 14, 2026

Developments

Valion advances integrated biodefense, immunology platform

Valion Bio (NASDAQ: VBIO) has provided an update for its Entolimod program—including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndrome (ARS) preparedness, a demonstrated...

July 14, 2026

Feature

Adaptin Bio is leveraging immune cell hitchhiking to target brain tumors

By Melane Sampson Michael J. Roberts, PhD, CEO and Co-founder of Adaptin Bio Adaptin Bio (OTCQB: APTN) is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering...

July 14, 2026

Developments

VERAXA, Ardigen launch drug discovery collaboration

VERAXA Biotech (NASDAQ: VRXA) has announced a collaboration with closely held AI partner Ardigen to support VERAXA’s growing BiTAC pipeline of T-cell engagers and antibody-drug conjugates. According to VERAXA, the...

July 13, 2026

Developments

Virax signs immune profiling product supply deal with Fosun

Virax Biolabs (NASDAQ: VRAX) has announced the signing of an exclusive commercial supply agreement with Fosun Diagnostics, a subsidiary of Fosun Pharma (600196.SS; 02196.HK), for its research-use-only ImmuneSelect...

July 13, 2026

Developments

FDA grants RPD to Thiogenesis’ TTI-0102 for Leigh syndrome

Thiogenesis Therapeutics (TSXV: TTI; OTCQX: TTIPF) has announced that the FDA has granted Rare Pediatric Disease (RPD) designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome. Upon approval of a...

July 13, 2026

Developments

MIRA reports positive results supporting MIRA-55 as non-opioid oral pain therapy

MIRA Pharmaceuticals (NASDAQ: MIRA) has announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the company’s oral drug candidate being developed as a non-opioid...

July 10, 2026

Developments

Rani and PegBio join forces to expand obesity pipeline

Rani Therapeutics Holdings (NASDAQ: RANI) has announced a research and development collaboration with PegBio (SEHK: 2565) to explore the delivery of multiple novel candidates from PegBio’s obesity and metabolic...

July 10, 2026

Author - Melane Sampson

Myricx to be acquired by Novartis for $1.5B

USPTO grants Immutep new patent for eftilagimod alfa combined with PD-1 pathway inhibitors

Envoy reports improvement in speech perception in trial of cochlear implant

Valion advances integrated biodefense, immunology platform

Adaptin Bio is leveraging immune cell hitchhiking to target brain tumors

VERAXA, Ardigen launch drug discovery collaboration

Virax signs immune profiling product supply deal with Fosun

FDA grants RPD to Thiogenesis’ TTI-0102 for Leigh syndrome

MIRA reports positive results supporting MIRA-55 as non-opioid oral pain therapy

Rani and PegBio join forces to expand obesity pipeline

Subscribe